Alembic Pharma shares rise 4% on receiving USFDA EIR for Vadodara facility
The USFDA conducted the inspection at Alembic Pharmaceuticals' Bioequivalence Facility in Vadodara from March 3 to March 7, 2025. The company had earlier informed the stock exchanges about the completion of the inspection.
- Sep 17, 2026,
- Updated Sep 17, 2026 1:28 PM IST
Shares of Alembic Pharmaceuticals Ltd, a vertically integrated Indian pharmaceutical company, rose 4 per cent in Wednesday's trade after the drugmaker announced that the US Food and Drug Administration (USFDA) issued an Establishment Inspection Report (EIR) and communicated the closure of its inspection at the company's Bioequivalence Facility in Vadodara, Gujarat.
The USFDA conducted the inspection at Alembic Pharmaceuticals' Bioequivalence Facility in Vadodara from March 3 to March 7, 2025. The company had earlier informed the stock exchanges about the completion of the inspection.
Alembic Pharmaceuticals shares were trading at Rs 835.40 on Wednesday, up 3.78% from their previous close of Rs 824.40. The stock opened at Rs 834.70 and touched an intraday high of Rs 855.60.
In its exchange filing dated September 16, 2026, the company said the USFDA has issued the EIR and communicated the closure of the inspection. Alembic Pharmaceuticals requested the stock exchanges to take the update on record.
The latest disclosure relates specifically to the USFDA inspection of the company's Bioequivalence Facility in Vadodara. The company did not provide details of the EIR or specify any observations in the exchange filing.
The update follows the company's March 2025 disclosure regarding the completion of the USFDA inspection at the facility. The latest filing confirms that the inspection conducted during March 2025 has now been closed.
Shares of Alembic Pharmaceuticals Ltd, a vertically integrated Indian pharmaceutical company, rose 4 per cent in Wednesday's trade after the drugmaker announced that the US Food and Drug Administration (USFDA) issued an Establishment Inspection Report (EIR) and communicated the closure of its inspection at the company's Bioequivalence Facility in Vadodara, Gujarat.
The USFDA conducted the inspection at Alembic Pharmaceuticals' Bioequivalence Facility in Vadodara from March 3 to March 7, 2025. The company had earlier informed the stock exchanges about the completion of the inspection.
Alembic Pharmaceuticals shares were trading at Rs 835.40 on Wednesday, up 3.78% from their previous close of Rs 824.40. The stock opened at Rs 834.70 and touched an intraday high of Rs 855.60.
In its exchange filing dated September 16, 2026, the company said the USFDA has issued the EIR and communicated the closure of the inspection. Alembic Pharmaceuticals requested the stock exchanges to take the update on record.
The latest disclosure relates specifically to the USFDA inspection of the company's Bioequivalence Facility in Vadodara. The company did not provide details of the EIR or specify any observations in the exchange filing.
The update follows the company's March 2025 disclosure regarding the completion of the USFDA inspection at the facility. The latest filing confirms that the inspection conducted during March 2025 has now been closed.